3 results
Primary Objectives* Phase 1b lead-in: To assess safety and tolerability of a single dose level of avelumab in combination withincreasing dose levels of other immune modulators in combination with a single doselevel of avelumab in patients with…
The primary objective is:* To evaluate RBC transfusion independence (RBC-TI) of luspatercept compared with placebo for the treatment of anemia due to IPSS-R very low, low, or intermediate risk MDS in subjects with ring sideroblasts (* 15%) who…
Part A:- Evaluate the safety of increasing doses of a single dose continuous DMT infusion over 90 minutes in healthy smokers - Characterize the pharmacokinetics of a single dose DMT administered continuously over 90 minutes in healthy smokers -…